Abstract: The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from —SO2NH2, —SO2NHMe or —SO2NMe2, —SO2NHEt, or —SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.
Type:
Grant
Filed:
April 18, 2013
Date of Patent:
June 23, 2015
Assignee:
CHANGZHOU LE SUN PHARMACEUTICALS LIMITED
Abstract: The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from —SO2NH2, —SO2NHMe or —SO2NMe2, —SO2NHEt, or —SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated.
Type:
Application
Filed:
April 18, 2013
Publication date:
April 16, 2015
Applicant:
CHANGZHOU LE SUN PHARMACEUTICALS LIMITED
Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate or physiologically hydrolysable, solubilizing or immobilizable derivative thereof; wherein: any one or two of X.
Type:
Grant
Filed:
June 21, 2011
Date of Patent:
September 9, 2014
Assignee:
Changzhou Le Sun Pharmaceuticals Limited
Inventors:
Shudong Wang, Osama Chahrour, Tiangong Lu, Anran Hu